This study is only for nGBM. They have already run some rGBM. If the crossover data is showing strong then they may not have to run a randomized blinded trial for rGBM. Perhaps just an open label confirmation trial. Some countries might not need it. No one knows exactly. Anything is possible.
Market Data 
Markets 
AI
